-
1Academic Journal
المؤلفون: O. A. Suvorova, A. F. Kravchenko, N. S. Val, N. M. Krasnova, Ya. V. Chertovskikh, Z. A. Rudykh, E. A. Alekseeva, O. L. Vasileva, N. E. Evdokimova, D. V. Ivashchenko, D. A. Sychev, О. А. Суворова, А. Ф. Кравченко, Н. С. Валь, Н. М. Краснова, Я. В. Чертовских, З. А. Рудых, Е. А. Алексеева, О. Л. Васильева, Н. Е. Евдокимова, Д. В. Иващенко, Д. А. Сычёв
المصدر: Pharmacogenetics and Pharmacogenomics; № 1 (2019); 35-40 ; Фармакогенетика и фармакогеномика; № 1 (2019); 35-40 ; 2588-0527 ; 2686-8849
مصطلحات موضوعية: русские, isoniazid, pharmacogenetics, NAT2, yakutians, russians, изониазид, фармакогенетика, якуты
وصف الملف: application/pdf
Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/146/146; Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.; Treatment of tuberculosis. World Heal. Organ. 2010.; Matsumoto T, Ohno M, Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics. 2014;15:601–607. DOI:10.2217/pgs.14.38; Wang P, Pradhan K, Zhong X, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm. Sin. B. 2016;6(5):384-392.; Cai Y, Yi JY, Zhou CH, Shen XZ. Pharmacogenetic Study of DrugMetabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis. PLoS One. 2012;7(10):1–8.; Zhang M, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2018;84(12):2747–2760.; Mahto H, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence metaanalysis as evidence. Biosci. Rep. 2018;39(1): BSR20180845.; Wang PY, Xie SY, Hao Q, et al. Jiang. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: A meta-analysis. Int. J. Tuberc. Lung Dis. 2012;16(5):589–595.; Shi J, Xie M, Wang J, et al. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics. 2015;16:2083–2097.; Donald PR, et al. The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of Isoniazid. Clin. Infect. Dis. Publushed by Oxford Univ. Press. 2004;39(10): 1425–1430.; Weiner M, et al. Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. Am. J. Respir. Crit. Care Med. 2003;167:1341–1347.; Kinzig-schippers M, et al. Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses? Society. 2005;49(5):1733–1738.; Hasunuma T, Azuma J, Ohno M, et al. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur. J. Clin. Pharmacol. 2007;63(10):927–933.; Azuma J, Ohno M, Kubota R. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis : A randomized controlled trial for pharmacogenetics-based therapy. Pharmacogenetics. 2013; 1091–1101.; Zhu R, et al. The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid. J Clin Pharmacol. 2009;6(11):1249–1254.; Jagodziński J, et al. Correlation of N-Acetyltransferase 2 Genotype with Isoniazid Acetylation in Polish Tuberculosis Patients. Biomed Res. Int. 2013;2013(Figure 1):1–5.; Министерство здравоохранения Республики Саха (Якутия) ГБУ «Республиканский детский туберкулезный санаторий имени Т.П. Дмитриевой». Статистический отчет за 2018 год.; Diallo I, Vangenot C, Sanchez-mazas A, et al. Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa. BMC Evol. Biol. 2015;1–20.; Toure A, et al. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol. Reports. 2016;3:826–831.; Mortensen HM, et al. Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations. Pharmacogenomics. 2015;12(11):1545–1558.; Tang H, et al. Genetic Structure , Self-Identified Race. Ethnicity, and Confounding in Case-Control Association Studies. 2005;268–275.; Sabbagh A, Darlu P, Crouau-roy B, Poloni ES. Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey. PLoS One. 2011; 6(4):e18507. DOI:10.1371/journal.pone.0018507; Hein DW. N-acetyltransferase 2 genetic polymorphism : effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006;2:1649–1658.; Kurose K, Sugiyama E, Saito Y. Population Differences in Major Functional Polymorphisms of Pharmacokinetics / pharmacodynamics-related Genes in Eastern Asians and Europeans : Implications in the Clinical Trials for Novel Drug Development. Drug metabolism and pharmacokinetics. 2012;27(1):1–18.; Gra O, et al. Microarray-Based Detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 Allele Frequencies in Native Russians. Genet. Test. Mol. Biomarkers. 2010;14(3):329–342.; https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/146